VCM
VYNE icon

Versant Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Versant Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2
Closed – – 1550
2020
Q3 		$0 Hold
2
– – ﹤0.01% 1525
2020
Q2 		$0 Buy
+2
New +$271 ﹤0.01% 1575
2020
Q1 		– Sell
-1
Closed – – 1710
2019
Q4 		$0 Buy
+1
New +$333 ﹤0.01% 1602

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Versant Capital Management's VYNE Position: Q4 2020 in Review

Versant Capital Management sold out of VYNE Therapeutics (VYNE) in Q4 2020, closing a stake of 2 shares.

Versant Capital Management first reported a position in VYNE in Q4 2019 and held it in 3 quarters. The position peaked at $0 in Q3 2020. 104 funds tracked by Wall St. Rank hold VYNE as of Q4 2020.

  • Versant Capital Management reported no remaining VYNE Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Versant Capital Management sold 2 VYNE Therapeutics shares in Q4 2020.
  • Versant Capital Management first reported a position in VYNE Therapeutics in Q4 2019 and held it in 3 quarters.
  • Versant Capital Management's VYNE Therapeutics position peaked at $0 in Q3 2020.
  • 104 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2020.

Based on Versant Capital Management's 13F filing for Q4 2020, filed 8 Feb 2021.